Lauren Santye, Assistant Editor

Descovy contains 2 HIV nucleoside analog reverse transcriptase inhibitors, emtricitabine, and tenofovir alafenamide.

Descovy is not a complete regimen and must be used in combination with other antiretroviral agents for the treatment of HIV.

Unmet healthcare needs create significant financial burdens on overall system.

California man with osteogenesis imperfecta beats HCV after treatment with Harvoni.

Patients with conditions such as rheumatoid arthritis or Crohn’s disease found to benefit from at-home treatment.

Risk of cardiovascular events increases in HIV patients who defer or interrupt treatment.

Sites like Facebook and Twitter allow patients with rare diseases to share their experiences.

New technique could soon move to clinical trials in prostate cancer.

Individualized approach allows for creation of widespread models of patient-specific tumors.

DNA screening technology up to 10,000 times more sensitive than current tests for cancer and HIV.

Acceptance of pharmacist-written recommendation letters for heart failure significantly lower than diabetes.

HCV patients with cirrhosis and severe sepsis face elevated risk of organ failure.

Administering type 2 diabetes drugs to patients with maturity-onset diabetes of the young can cause harm.

Human epidermal growth factor receptor linked to success of chemotherapy.

Viral load predicts immune cell response in patients with HIV.

Bright white light therapy shows treats depressive symptoms in cancer patients.

Clinical benefit of 3 to 8 months found in some patients who received drugs that targeted tumors in the P13K/AKT/mTOR pathway.

Sulforaphane, which occurs naturally in several cruciferous vegetables, can change the activity of endogenous enzymes.

Recurrence Score test may help some women with breast cancer be spared of chemotherapy without experiencing disease progression.

Long-term use of senolytic drugs to clear damaged cells from the body can help prevent heart disease.

Chronic CIPN is a common side effect of chemotherapy that appears a month after treatment for cancer.

Reseach may lead to new therapeutic approaches that correct disease-causing RNA behaviors.

Plitidepsin (Aplidin) in combination with dexamethasone found to reduce risk of progression and death from multiple myeloma.

Plitidepsin (Aplidin) in combination with dexamethasone shows 35% reduction in the risk of progression or death over comparator drug in multiple myeloma.

Trioxacarcins disrupt cancer cell replication by binding and chemically-modifying genetic material.

Mucus can form a shield around cancerous cells to protect from chemotherapy drugs.

Researchers send alerts to practitioners believed to over-prescribe addictive substances like opioids and amphetamines.

Mesothelioma is resistant to available drugs, requiring the need for new treatments.

Transparency in the cost, pricing, and comparative value for all pharmaceutical products among proposed revisions.

Defitelio treats hepatic veno-occlusive disease in both adult and pediatric patients.